Stockscreener 앱 받기
10.70
2.82%
-0.31
시간 외 거래:
10.85
0.15
+1.40%
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Crestline Management LP Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Guggenheim Reiterates "Buy" Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat
What is B. Riley's Forecast for SNDX Q2 Earnings? - MarketBeat
Bayesian Capital Management LP Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Marshall Wace LLP Sells 977,280 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Algert Global LLC Buys 310,634 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - Yahoo Finance
Avidity Partners Management LP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $17.00 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Syndax Announces Participation in May Investor Conferences - The Manila Times
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results - simplywall.st
SNDX: Syndax Reveals Significant Phase 2 Trial Results for Revumenib | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.20 Average Target Price from Analysts - MarketBeat
Syndax Announces Publication of Pivotal Revumenib Data in - GlobeNewswire
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood - Yahoo Finance
Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call - TipRanks
SNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenhei - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim | SNDX Stock News - GuruFocus
Scotiabank raises Syndax stock target to $17 on strong sales By Investing.com - Investing.com Canada
Syndax (SNDX) Price Target Increased by BofA Following Promising Updates | SNDX Stock News - GuruFocus
BofA raises Syndax stock price target to $26 on strong Q1 update - Investing.com Canada
Syndax Pharmaceuticals Q1 Loss Widens - marketscreener.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highligh - GuruFocus
SNDX Reports Strong Revenue and Cash Position, Focuses on Growth - GuruFocus
Syndax Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2025 EPS estimates - Investing.com Canada
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax: Q1 Earnings Snapshot - MySA
Syndax Pharmaceuticals earnings beat by $0.26, revenue topped estimates - Investing.com Canada
Syndax Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.98 Beats Estimates, Revenue Surges to $20 Million - GuruFocus
Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong - Investing.com India
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong By Investing.com - Investing.com South Africa
SNDX Reports Impressive Q1 Revenue, Exceeds Market Expectations | SNDX Stock News - GuruFocus
Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Revenue $20M, vs. FactSet Est of $15.6M - marketscreener.com
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday - MarketBeat
0.84%
0.15%
자본화:
|
볼륨(24시간):